Cognition Therapeutics (CGTX) published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine in adults with mild-to-moderate Alzheimer’s disease. The manuscript, titled Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Clinical Trial of the Alzheimer’s Disease Drug Candidate, CT1812, was published in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. In the SEQUEL study, zervimesine treatment resulted in consistent trends of improvement across all prespecified EEG parameters, including the prominence of certain EEG frequencies associated with Alzheimer’s disease. Slower frequencies termed “theta” waves were reduced after 29 days of zervimesine treatment compared to placebo. This suggests zervimesine may normalize the function of neurons and synapses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics ot present data from zervimesine Phase 2 study
- Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine
- Cognition completes End-of-Phase 2 meeting with FDA for zervimesine
- Cognition Therapeutics’ Promising Clinical Progress and Regulatory Advancements Justify Buy Rating
- Cognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment